Pasar al contenido principal

DAÑO Y REPARACION DEL ADN EN EL GENOMA COMPLETO PARA ENTENDER LOS PROCESOS MUTACIONALES EN TUMORES

RTI2018-094095-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Hotspot propensity across mutational processes

  • Arnedo Pac, Claudia
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
The sparsity of mutations observed across tumours hinders our ability to study mutation rate variability at nucleotide resolution. To circumvent this, here we investigated the propensity of mutational processes to form mutational hotspots as a readout of their mutation rate variability at single base resolution. Mutational signatures 1 and 17 have the highest hotspot propensity (5-78 times higher than other processes). After accounting for trinucleotide mutational probabilities, sequence composition and mutational heterogeneity at 10 Kbp, most (94-95%) signature 17 hotspots remain unexplained, suggesting a significant role of local genomic features. For signature 1, the inclusion of genome-wide distribution of methylated CpG sites into models can explain most (80-100%) of the hotspot propensity. There is an increased hotspot propensity of signature 1 in normal tissues and de novo germline mutations. We demonstrate that hotspot propensity is a useful readout to assess the accuracy of mutation rate models at nucleotide resolution. This new approach and the findings derived from it open up new avenues for a range of somatic and germline studies investigating and modelling mutagenesis., This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation has made available to the study. We acknowledge the technical contributions of Iker Reyes-Salazar and Loris Mularoni to HotspotFinder algorithm and annotations. NL-B acknowledges funding from the European Research Council (consolidator grant 682398) and the European Regional Development Fund/Spanish Ministry of Science, Innovation and Universities—Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Fundación Científica Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). This work has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMINENT) funded by Cancer Research UK (CGCATF-2021/100008), National Cancer Institute (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). CA-P was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The genomic landscape of 2,023 colorectal cancers

  • Cornish, Alex J.
  • Arnedo Pac, Claudia
  • López Bigas, Núria
  • Houlston, Richard S.
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11-13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care., R.S.H., I.P.M.T. and N.L.-B. are supported by the Wellcome Trust (214388), T.A.G. and A.S are supported by the Wellcome Trust (202778/B/16/Z). I.P.M.T. is supported by Cancer Research UK (C6199/A27327). R.S.H. is supported by Cancer Research UK (C1298/A8362). D.C.W. is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). A. Sottoriva is supported by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771 and DRCNPG-May21\100001). P.Q. and H.M.W. are supported by Cancer Research UK Grand Challenge Initiative (OPTIMISTICC C10674/A27140). P.Q. is also supported by Yorkshire Cancer Research L386 and is a National Institute of Health Senior Investigator. B.N was funded through the Cancer Research UK Birmingham Centre award (C17422/A25154). C.A.-P. was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011). L.B.A was supported by grants from the US National Institutes of Health, including NIEHS R01ES032547 and NCI R01CA269919. G.C. is supported by the Italian Association for Cancer Research (AIRC) under MFAG 2020-ID 24913. We acknowledge funding from the National Institute of Health (NCI U54 CA217376) to A.S and T.A.G. This work was also supported by a Wellcome Trust award to the Centre for Evolution and Cancer at the ICR (105104/Z/14/Z). D.N.C. is supported a by Cancer Research UK Advanced Clinician Scientist Fellowship award (C26642/A27963). D.N.C., D.C.W. and A.F. acknowledge support from the Oxford NIHR Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We are grateful to all participants and other individuals involved in the study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The genomic landscape of 2,023 colorectal cancers

  • Cornish, Alex J.
  • Arnedo Pac, Claudia
  • López Bigas, Núria
  • Houlston, Richard S.
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11-13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care., R.S.H., I.P.M.T. and N.L.-B. are supported by the Wellcome Trust (214388), T.A.G. and A.S are supported by the Wellcome Trust (202778/B/16/Z). I.P.M.T. is supported by Cancer Research UK (C6199/A27327). R.S.H. is supported by Cancer Research UK (C1298/A8362). D.C.W. is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). A. Sottoriva is supported by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771 and DRCNPG-May21\100001). P.Q. and H.M.W. are supported by Cancer Research UK Grand Challenge Initiative (OPTIMISTICC C10674/A27140). P.Q. is also supported by Yorkshire Cancer Research L386 and is a National Institute of Health Senior Investigator. B.N was funded through the Cancer Research UK Birmingham Centre award (C17422/A25154). C.A.-P. was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011). L.B.A was supported by grants from the US National Institutes of Health, including NIEHS R01ES032547 and NCI R01CA269919. G.C. is supported by the Italian Association for Cancer Research (AIRC) under MFAG 2020-ID 24913. We acknowledge funding from the National Institute of Health (NCI U54 CA217376) to A.S and T.A.G. This work was also supported by a Wellcome Trust award to the Centre for Evolution and Cancer at the ICR (105104/Z/14/Z). D.N.C. is supported a by Cancer Research UK Advanced Clinician Scientist Fellowship award (C26642/A27963). D.N.C., D.C.W. and A.F. acknowledge support from the Oxford NIHR Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We are grateful to all participants and other individuals involved in the study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hotspot propensity across mutational processes

  • Arnedo Pac, Claudia
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
The sparsity of mutations observed across tumours hinders our ability to study mutation rate variability at nucleotide resolution. To circumvent this, here we investigated the propensity of mutational processes to form mutational hotspots as a readout of their mutation rate variability at single base resolution. Mutational signatures 1 and 17 have the highest hotspot propensity (5-78 times higher than other processes). After accounting for trinucleotide mutational probabilities, sequence composition and mutational heterogeneity at 10 Kbp, most (94-95%) signature 17 hotspots remain unexplained, suggesting a significant role of local genomic features. For signature 1, the inclusion of genome-wide distribution of methylated CpG sites into models can explain most (80-100%) of the hotspot propensity. There is an increased hotspot propensity of signature 1 in normal tissues and de novo germline mutations. We demonstrate that hotspot propensity is a useful readout to assess the accuracy of mutation rate models at nucleotide resolution. This new approach and the findings derived from it open up new avenues for a range of somatic and germline studies investigating and modelling mutagenesis., This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation has made available to the study. We acknowledge the technical contributions of Iker Reyes-Salazar and Loris Mularoni to HotspotFinder algorithm and annotations. NL-B acknowledges funding from the European Research Council (consolidator grant 682398) and the European Regional Development Fund/Spanish Ministry of Science, Innovation and Universities—Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Fundación Científica Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). This work has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMINENT) funded by Cancer Research UK (CGCATF-2021/100008), National Cancer Institute (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). CA-P was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The evolution of relapse of adult T cell acute lymphoblastic leukemia

  • Sentís, Inés|||0000-0001-8320-9579
  • González, Santiago
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Muiños, Ferran|||0000-0002-4651-4168
  • González Gil, Celia|||0000-0002-7582-1482
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • González, Jéssica
  • Fernández Ibarrondo, Lierni|||0000-0003-2612-0484
  • Mularoni, Loris|||0000-0001-7053-7717
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
Background: Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. A higher percentage of the adult patients relapse, compared to children. It is thus essential to study the mechanisms of relapse of adult T-ALL cases. Results: We profile whole-genome somatic mutations of 19 primary T-ALLs from adult patients and the corresponding relapse malignancies and analyze their evolution upon treatment in comparison with 238 pediatric and young adult ALL cases. We compare the mutational processes and driver mutations active in primary and relapse adult T-ALLs with those of pediatric patients. A precise estimation of clock-like mutations in leukemic cells shows that the emergence of the relapse clone occurs several months before the diagnosis of the primary T-ALL. Specifically, through the doubling time of the leukemic population, we find that in at least 14 out of the 19 patients, the population of relapse leukemia present at the moment of diagnosis comprises more than one but fewer than 10 blasts. Using simulations, we show that in all patients the relapse appears to be driven by genetic mutations. Conclusions: The early appearance of a population of leukemic cells with genetic mechanisms of resistance across adult T-ALL cases constitutes a challenge for treatment. Improving early detection of the malignancy is thus key to prevent its relapse.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The evolution of hematopoietic cells under cancer therapy

  • Pich, Oriol|||0000-0002-1956-1882
  • Cortés Bullich, Albert|||0000-0002-6260-901X
  • Muiños, Ferran|||0000-0002-4651-4168
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
Chemotherapies may increase mutagenesis of healthy cells and change the selective pressures in tissues, thus influencing their evolution. However, their contributions to the mutation burden and clonal expansions of healthy somatic tissues are not clear. Here, exploiting the mutational footprint of some chemotherapies, we explore their influence on the evolution of hematopoietic cells. Cells of Acute Myeloid Leukemia (AML) secondary to treatment with platinum-based drugs show the mutational footprint of these drugs, indicating that non-malignant blood cells receive chemotherapy mutations. No trace of the 5-fluorouracil (5FU) mutational signature is found in AMLs secondary to exposure to 5FU, suggesting that cells establishing the leukemia could be quiescent during treatment. Using the platinum-based mutational signature as a barcode, we determine that the clonal expansion originating the secondary AMLs begins after the start of the cytotoxic treatment. Its absence in clonal hematopoiesis cases is consistent with the start of the clonal expansion predating the exposure to platinum-based drugs.